The epigenetic effect of nicotine on dopamine D1 receptor expression in rat prefrontal cortex

Synapse

Volumn 67, Issue 9, 2013, Pages 545-552

  Gozen, Oguz ^a,b   Balkan, Burcu ^a,b   Yildirim, Emre ^c   Koylu, Ersin O ^a,b   Pogun, Sakire ^b  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b EGE UNIVERSITY   (Turkey)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

Dopamine; DRD1; Epigenetic; Histone acetylation; Nicotine; Prefrontal cortex

Indexed keywords

DOPAMINE 1 RECEPTOR; HISTONE H4; MESSENGER RNA; NICOTINE; SODIUM CHLORIDE; TRANSCRIPTION FACTOR;

ANIMAL TISSUE; ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORPUS STRIATUM; EPIGENETICS; GENE AMPLIFICATION; GENE EXPRESSION; GENE SEQUENCE; GENETIC REGULATION; HISTONE ACETYLATION; HOMOGENATE; MALE; NONHUMAN; PERFUSION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; RNA ISOLATION; VENTRAL TEGMENTUM;

DOPAMINE; DRD1; EPIGENETIC; HISTONE ACETYLATION; NICOTINE; PREFRONTAL CORTEX;

ACETYLATION; ANIMALS; CHROMATIN; CORPUS STRIATUM; EPIGENESIS, GENETIC; HISTONES; INJECTIONS, SUBCUTANEOUS; MALE; NICOTINE; PREFRONTAL CORTEX; PROMOTER REGIONS, GENETIC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; TRANSCRIPTION, GENETIC; VENTRAL TEGMENTAL AREA;

EID: 84880614279     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21659     Document Type: Article

References (79)

1. Abdolmaleky HM, Smith CL, Zhou JR, Thiagalingam S. 2008. Epigenetic alterations of the dopaminergic system in major psychiatric disorders. Methods Mol Biol 448:187-212.
2. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. 2002. Molecular biology of the cell, 4th ed. New York: Garland Publishing.
3. Balfour DJ. 2004. The neurobiology of tobacco dependence: A preclinical perspective on the role of the dopamine projections to the nucleus accumbens [corrected]. Nicotine Tob Res 6(6):899-912.
4. Belluardo N, Olsson PA, Mudo G, Sommer WH, Amato G, Fuxe K. 2005. Transcription factor gene expression profiling after acute intermittent nicotine treatment in the rat cerebral cortex. Neuroscience 133(3):787-796.
5. Benwell ME, Balfour DJ. 1992. The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br J Pharmacol 105(4):849-856.
6. Benwell ME, Balfour DJ. 1997. Regional variation in the effects of nicotine on catecholamine overflow in rat brain. Eur J Pharmacol 325(1):13-20.
7. Benwell ME, Balfour DJ, Birrell CE. 1995. Desensitization of the nicotine-induced mesolimbic dopamine responses during constant infusion with nicotine. Br J Pharmacol 114(2):454-460.
8. Bergson C, Mrzljak L, Smiley JF, Pappy M, Levenson R, Goldman-Rakic PS. 1995. Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain. J Neurosci 15(12):7821-7836.
9. Boules M, Oliveros A, Liang Y, Williams K, Shaw A, Robinson J, Fredrickson P, Richelson E. 2011. A neurotensin analog, NT69L, attenuates intravenous nicotine self-administration in rats. Neuropeptides 45(1):9-16.
10. Brenhouse HC, Sonntag KC, Andersen SL. 2008. Transient D1 dopamine receptor expression on prefrontal cortex projection neurons: Relationship to enhanced motivational salience of drug cues in adolescence. J Neurosci 28(10):2375-2382.
11. Cadoni C, Di Chiara G. 2000. Differential changes in accumbens shell and core dopamine in behavioral sensitization to nicotine. Eur J Pharmacol 387(3):R23-R25.
12. Caine SB, Heinrichs SC, Coffin VL, Koob GF. 1995. Effects of the dopamine D-1 antagonist SCH 23390 microinjected into the accumbens, amygdala or striatum on cocaine self-administration in the rat. Brain Res 692(1-2):47-56.
13. Carboni E, Barros VG, Ibba M, Silvagni A, Mura C, Antonelli MC. 2010. Prenatal restraint stress: An in vivo microdialysis study on catecholamine release in the rat prefrontal cortex. Neuroscience 168(1):156-166.
14. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, Frisch M, Bayerlein M, Werner T. 2005. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21(13):2933-2942.
15. Chakrabarti SK, James JC, Mirmira RG. 2002. Quantitative assessment of gene targeting in vitro and in vivo by the pancreatic transcription factor, Pdx1. Importance of chromatin structure in directing promoter binding. J Biol Chem 277(15):13286-13293.
16. Chase KA, Sharma RP. 2012. Nicotine induces chromatin remodelling through decreases in the methyltransferases GLP, G9a, Setdb1 and levels of H3K9me2. Int J Neuropsychopharmacol 1-10. Epub ahead of print. DOI: http://dx.doi.org/10.1017/S1461145712001101.
17. Clarke PB, Fu DS, Jakubovic A, Fibiger HC. 1988. Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J Pharmacol Exp Ther 246(2):701-708.
18. Corrigall WA, Coen KM. 1991. Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology 104(2):171-176.
19. Damaj MI, Martin BR. 1993. Is the dopaminergic system involved in the central effects of nicotine in mice? Psychopharmacology 111(1):106-108.
20. David HN, Ansseau M, Abraini JH. 2005. Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate-putamen and nucleus accumbens of "intact" animals. Brain Res Brain Res Rev 50(2):336-360.
21. Dhanasekaran S, Doherty TM, Kenneth J. 2010. Comparison of different standards for real-time PCR-based absolute quantification. J Immunol Methods 354(1-2):34-39.
22. Di Chiara G. 2000. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 393(1-3):295-314.
23. Di Chiara G, Imperato A. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85(14):5274-5278.
24. Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, Mouradian MM, Young AB, Tanese N, Krainc D. 2002. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296(5576):2238-2243.
25. Everitt BJ, Robbins TW. 2005. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8(11):1481-1489.
26. Fredrickson P, Boules M, Yerbury S, Richelson E. 2003. Blockade of nicotine-induced locomotor sensitization by a novel neurotensin analog in rats. Eur J Pharmacol 458(1-2):111-118.
27. Gaspar P, Bloch B, Le Moine C. 1995. D1 and D2 receptor gene expression in the rat frontal cortex: Cellular localization in different classes of efferent neurons. Eur J Neurosci 7(5):1050-1063.
28. Godornes C, Leader BT, Molini BJ, Centurion-Lara A, Lukehart SA. 2007. Quantitation of rabbit cytokine mRNA by real-time RT-PCR. Cytokine 38(1):1-7.
29. Goold R, Hubank M, Hunt A, Holton J, Menon RP, Revesz T, Pandolfo M, Matilla-Duenas A. 2007. Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1. Hum Mol Genet 16(17):2122-2134.
30. Gotti C, Zoli M, Clementi F. 2006. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 27(9):482-491.
31. Grenhoff J, Aston-Jones G, Svensson TH. 1986. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol Scand 128(3):351-358.
32. Heidbreder CA, Groenewegen HJ. 2003. The medial prefrontal cortex in the rat: Evidence for a dorso-ventral distinction based upon functional and anatomical characteristics. Neurosci Biobehav Rev 27(6):555-579.
33. Huang W, Ma JZ, Payne TJ, Beuten J, Dupont RT, Li MD. 2008. Significant association of DRD1 with nicotine dependence. Hum Genet 123(2):133-140.
34. Hyman SE. 2005. Addiction: A disease of learning and memory. Am J Psychiatry 162(8):1414-1422.
35. Imperato A, Mulas A, Di Chiara G. 1986. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 132(2-3):337-338.
36. Jacobs I, Anderson DJ, Surowy CS, Puttfarcken PS. 2002. Differential regulation of nicotinic receptor-mediated neurotransmitter release following chronic (-)-nicotine administration. Neuropharmacology 43(5):847-856.
37. Janhunen S, Ahtee L. 2004. Comparison of the effects of nicotine and epibatidine on the striatal extracellular dopamine. Eur J Pharmacol 494(2-3):167-177.
38. Kalivas PW, Volkow N, Seamans J. 2005. Unmanageable motivation in addiction: A pathology in prefrontal-accumbens glutamate transmission. Neuron 45(5):647-650.
39. Kanyt L, Stolerman IP, Chandler CJ, Saigusa T, Pogun S. 1999. Influence of sex and female hormones on nicotine-induced changes in locomotor activity in rats. Pharmacol Biochem Behav 62(1):179-187.
40. Landais E, El-Khoury V, Prevost A, Dufer J, Liautaud-Roger F. 2005. Nicotine induces chromatin changes and c-Jun up-regulation in HL-60 leukemia cells. Oncol Rep 14(6):1553-1558.
41. Le Foll B, Diaz J, Sokoloff P. 2003. Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse 47(3):176-183.
42. Le Foll B, Gallo A, Le Strat Y, Lu L, Gorwood P. 2009. Genetics of dopamine receptors and drug addiction: A comprehensive review. Behav Pharmacol 20(1):1-17.
43. Lecca D, Cacciapaglia F, Valentini V, Gronli J, Spiga S, Di Chiara G. 2006. Preferential increase of extracellular dopamine in the rat nucleus accumbens shell as compared to that in the core during acquisition and maintenance of intravenous nicotine self-administration. Psychopharmacology 184(3-4):435-446.
44. Leikola-Pelho T, Jackson DM. 1992. Preferential stimulation of locomotor activity by ventral tegmental microinjections of (-)-nicotine. Pharmacol Toxicol 70(1):50-52.
45. Levin ED, Simon BB. 1998. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 138(3-4):217-230.
46. Levin ED, Torry D, Christopher NC, Yu X, Einstein G, Schwartz-Bloom RD. 1997. Is binding to nicotinic acetylcholine and dopamine receptors related to working memory in rats? Brain Res Bull 43(3):295-304.
47. Levine A, Huang Y, Drisaldi B, Griffin EA, Jr., Pollak DD, Xu S, Yin D, Schaffran C, Kandel DB, Kandel ER. 2011. Molecular mechanism for a gateway drug: epigenetic changes initiated by nicotine prime gene expression by cocaine. Sci Transl Med 3(107):107ra109.
48. Li MD, Kane JK, Wang J, Ma JZ. 2004. Time-dependent changes in transcriptional profiles within five rat brain regions in response to nicotine treatment. Brain Res Mol Brain Res 132(2):168-180.
49. Liang Y, Boules M, Shaw AM, Williams K, Fredrickson P, Richelson E. 2008. Effect of a novel neurotensin analog, NT69L, on nicotine-induced alterations in monoamine levels in rat brain. Brain Res 1231:6-15.
50. Lidow MS, Koh PO, Arnsten AF. 2003. D1 dopamine receptors in the mouse prefrontal cortex: Immunocytochemical and cognitive neuropharmacological analyses. Synapse 47(2):101-108.
51. Livingstone PD, Wonnacott S. 2009. Nicotinic acetylcholine receptors and the ascending dopamine pathways. Biochem Pharmacol 78(7):744-755.
52. London ED, Connolly RJ, Szikszay M, Wamsley JK, Dam M. 1988. Effects of nicotine on local cerebral glucose utilization in the rat. J Neurosci 8(10):3920-3928.
53. Marshall DL, Redfern PH, Wonnacott S. 1997. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: Comparison of naive and chronic nicotine-treated rats. J Neurochem 68(4):1511-1519.
54. Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, Craig CR, Collins AC, Damaj MI, Donny EC, Gardiner PS, Grady SR, Heberlein U, Leonard SS, Levin ED, Lukas RJ, Markou A, Marks MJ, McCallum SE, Parameswaran N, Perkins KA, Picciotto MR, Quik M, Rose JE, Rothenfluh A, Schafer WR, Stolerman IP, Tyndale RF, Wehner JM, Zirger JM. 2007. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology 190(3):269-319.
55. McGregor A, Roberts DC. 1993. Dopaminergic antagonism within the nucleus accumbens or the amygdala produces differential effects on intravenous cocaine self-administration under fixed and progressive ratio schedules of reinforcement. Brain Res 624(1-2):245-252.
56. Nisell M, Nomikos GG, Hertel P, Panagis G, Svensson TH. 1996. Condition-independent sensitization of locomotor stimulation and mesocortical dopamine release following chronic nicotine treatment in the rat. Synapse 22(4):369-381.
57. Pastor V, Host L, Zwiller J, Bernabeu R. 2011. Histone deacetylase inhibition decreases preference without affecting aversion for nicotine. J Neurochem 116(4):636-645.
58. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates. San Diego (CA): Academic Press.
59. Pierce RC, Kumaresan V. 2006. The mesolimbic dopamine system: The final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 30(2):215-238.
60. Pontieri FE, Tanda G, Orzi F, Di Chiara G. 1996. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382(6588):255-257.
61. Ranaldi R, Wise RA. 2001. Blockade of D1 dopamine receptors in the ventral tegmental area decreases cocaine reward: Possible role for dendritically released dopamine. J Neurosci 21(15):5841-5846.
62. Reavill C, Stolerman IP. 1990. Locomotor activity in rats after administration of nicotinic agonists intracerebrally. Br J Pharmacol 99(2):273-278.
63. Renthal W, Nestler EJ. 2008. Epigenetic mechanisms in drug addiction. Trends Mol Med 14(8):341-350.
64. Schilstrom B, Nomikos GG, Nisell M, Hertel P, Svensson TH. 1998. N-methyl-d-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience 82(3):781-789.
65. Seamans JK, Yang CR. 2004. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74(1):1-58.
66. Shahbazian MD, Zhang K, Grunstein M. 2005. Histone H2B ubiquitylation controls processive methylation but not monomethylation by Dot1 and Set1. Mol Cell 19(2):271-277.
67. Shearman E, Fallon S, Sershen H, Lajtha A. 2008. Nicotine-induced monoamine neurotransmitter changes in the brain of young rats. Brain Res Bull 76(6):626-639.
68. Shearman E, Rossi S, Sershen H, Hashim A, Lajtha A. 2005. Locally administered low nicotine-induced neurotransmitter changes in areas of cognitive function. Neurochem Res 30(8):1055-1066.
69. Spina L, Fenu S, Longoni R, Rivas E, Di Chiara G. 2006. Nicotine-conditioned single-trial place preference: Selective role of nucleus accumbens shell dopamine D1 receptors in acquisition. Psychopharmacology 184(3-4):447-455.
70. Steketee JD. 2003. Neurotransmitter systems of the medial prefrontal cortex: Potential role in sensitization to psychostimulants. Brain Res Brain Res Rev 41(2-3):203-228.
71. Takeuchi Y, Miyamoto E, Fukunaga K. 2002. Activation of the rat dopamine D2 receptor promoter by mitogen-activated protein kinase and Ca2+/calmodulin-dependent protein kinase II pathways. J Neurochem 83(4):784-796.
72. Tsukada H, Miyasato K, Nishiyama S, Fukumoto D, Kakiuchi T, Domino EF. 2005. Nicotine normalizes increased prefrontal cortical dopamine D1 receptor binding and decreased working memory performance produced by repeated pretreatment with MK-801: A PET study in conscious monkeys. Neuropsychopharmacology 30(12):2144-2153.
73. Vezina P, McGehee DS, Green WN. 2007. Exposure to nicotine and sensitization of nicotine-induced behaviors. Progress Neuropsychopharmacol Biol Psychiatry 31(8):1625-1638.
74. Volkow ND. 2011. Epigenetics of nicotine: Another nail in the coughing. Sci Transl Med 3(107):107ps143.
75. Wise RA, Bozarth MA. 1987. A psychomotor stimulant theory of addiction. Psychol Rev 94(4):469-492.
76. Wong AC, Shetreat ME, Clarke JO, Rayport S. 1999. D1- and D2-like dopamine receptors are co-localized on the presynaptic varicosities of striatal and nucleus accumbens neurons in vitro. Neuroscience 89(1):221-233.
77. Wonnacott S, Sidhpura N, Balfour DJ. 2005. Nicotine: From molecular mechanisms to behaviour. Curr Opin Pharmacol 5(1):53-59.
78. Yang Y, Hwang CK, Junn E, Lee G, Mouradian MM. 2000. ZIC2 and Sp3 repress Sp1-induced activation of the human D1A dopamine receptor gene. J Biol Chem 275(49):38863-38869.
79. Yin JL, Shackel NA, Zekry A, McGuinness PH, Richards C, Putten KV, McCaughan GW, Eris JM, Bishop GA. 2001. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green I. Immunol Cell Biol 79(3):213-221.